Common Use Cycles: 612 weeks of use 48 weeks of rest (off-cycle) Note: These figures are estimations only based on species scaling
Most of the peptides examined in the studies (especially in the papers where this mechanism is mentioned) contain specific sequences that allow them to cross the lipid membrane, such as the so-called cell-penetrating peptides (CPPs)
Sure, shedding might be a temporary side effect, but that doesnt make it easier to tolerate in the moment
Krolewski Research Division, Joslin Diabetes Center and Harvard Medical School Kevin Duffin Vice President, Aging Research, Eli Lilly Jonathan Wilson Senior Director, Eli Lilly and Company Pavo Imre Senior Medical Director, Eli Lilly & Co, Vienna Fergus Fleming Co-founder, Executive Director and CTO, RenalytixAI Anna Nowak-Szwed, Eiichiro Satake, and Sok Cin Tye Joslin Diabetes Center / Harvard Medical School researchers advancing translational proteomics and kidney disease biomarker research #cardiometabolic #immunology #pathology #Proteomics #KidneyDisease #Nephrology #Diabetes #Biomarkers #GLP1 #Tirzepatide #Olink #PrecisionMedicine #TranslationalResearch #EliLilly To view or add a comment, sign in Diabetes Conference Abstract | June 5, 2026 Using the custom Joslin Kidney Panel (JKP), an #Olink Focus 21-marker #proteomics panel developed by Olink for Joslin Diabetes Center, researchers from Harvard Medical School/Joslin Diabetes Center and Eli Lilly and Company showed that treatment with the dual GLP-1/GIP receptor agonist tirzepatide (#Mounjaro) significantly reduced circulating protein #biomarkers associated with progression to end-stage #kidney disease (#ESKD) in patients with type 2 diabetes (#T2D)
Among the endocytic proteins, we find adaptors from the early coat (Yap1801 and Yap1802), middle coat (Ent1, Ent2 and Sla1) and an auxilin-like protein involved in clathrin uncoating (Swa2)
